Related Experiment Video
Updated: Sep 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
The treatment of acute leukemia with continuous infusion L-Alanosine
Abstract:
L-Alanosine, an antitumor antibiotic was administered by members of the Southwest Oncology Group (SWOG) to 22 patients with resistant acute non-lymphocytic leukemia. The drug was administered by continuous infusion for five days at a starting dose of 125 mg/m2/day. Mucositis was dose-limiting in 15 patients and no marrow aplasia was attained. As administered, L-Alanosine is not an effective single agent in acute leukemia.
Related Concept Videos
Alzheimer's Disease: Treatment
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmaceutical Poisoning: Treatment Strategies
Continuous Renal Replacement Therapy

